Copy to clipboard 
LimaCorporate reported 2Q21 orthopedic revenue of €56.1 million (USD $68.4 million), +57.1% vs. 2Q20. Compared to the same period in 2019, the company’s sales declined -1.2%, mostly attributable to the ongoing severe impact of COVID in Italy relative to other regions.
LimaCorporate could soon make gains in the two attractive markets of cementless knees and digital enabling technology. April brought the first total shoulder arthroplasty using the company’s SmartSpace planning and guidance system. Then in May, the company saw the first implant of its cementless Trabecular Titanium Tibial Plate.
In the second half, the company expects further improvement in lagging regions and believes that there’s a significant backlog of deferred surgeries that could provide a tailwind in the coming quarters.
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
| 2Q21 | 2Q21 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $64.3 | $41.4 | $23.0 | 55.5% |
| Knees | $12.3 | $7.8 | $4.5 | 57.1% |
| Hips | $25.3 | $16.6 | $8.8 | 53% |
| Extremities | $26.7 | $17.0 | $9.7 | 57.1% |
| Trauma | $2.7 | $1.7 | $1.0 | 57.1% |
| Other (Promade) | $1.4 | $0.4 | $0.9 | 214.3% |
| Total | $68.4 | $43.6 | $24.9 | 57.1% |
| 1H21 | 1H20 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $121.0 | $104.5 | $16.5 | 15.8% |
| Knees | $23.1 | $21.1 | $1.9 | 9.1% |
| Hips | $46.8 | $41.2 | $5.6 | 13.7% |
| Extremities | $51.2 | $42.3 | $8.9 | 21.1% |
| Trauma | $5.1 | $4.4 | $0.7 | 16.4% |
| Other (Promade) | $2.0 | $1.1 | $0.9 | 78.6% |
| Total | $128.1 | $110.0 | $18.1 | 16.4% |
Geographic Sales
| 2Q21 | 2Q21 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $11.6 | $7.8 | $3.8 | 48.4% |
| OUS | $56.8 | $35.7 | $21.1 | 59.1% |
| EMEA | $41.1 | $25.3 | $15.8 | 62.6% |
| APAC | $13.0 | $8.3 | $4.7 | 57.1% |
| ROW | $2.7 | $2.2 | $0.6 | 25.7% |
| Total | $68.4 | $43.6 | $24.9 | 57.1% |
| 1H21 | 1H20 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $22.4 | $19.8 | $2.6 | 13% |
| OUS | $105.7 | $90.2 | $15.5 | 17.2% |
| EMEA | $75.7 | $64.5 | $11.2 | 17.3% |
| APAC | $24.9 | $19.6 | $5.4 | 27.4% |
| ROW | $5.1 | $6.2 | ($1.0) | (16.9%) |
| Total | $128.1 | $110.0 | $18.1 | 16.4% |
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
LimaCorporate reported 2Q21 orthopedic revenue of €56.1 million (USD $68.4 million), +57.1% vs. 2Q20. Compared to the same period in 2019, the company's sales declined -1.2%, mostly attributable to the ongoing severe impact of COVID in Italy relative to other regions.
LimaCorporate could soon make gains in the two attractive markets of...
LimaCorporate reported 2Q21 orthopedic revenue of €56.1 million (USD $68.4 million), +57.1% vs. 2Q20. Compared to the same period in 2019, the company’s sales declined -1.2%, mostly attributable to the ongoing severe impact of COVID in Italy relative to other regions.
LimaCorporate could soon make gains in the two attractive markets of cementless knees and digital enabling technology. April brought the first total shoulder arthroplasty using the company’s SmartSpace planning and guidance system. Then in May, the company saw the first implant of its cementless Trabecular Titanium Tibial Plate.
In the second half, the company expects further improvement in lagging regions and believes that there’s a significant backlog of deferred surgeries that could provide a tailwind in the coming quarters.
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
| 2Q21 | 2Q21 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $64.3 | $41.4 | $23.0 | 55.5% |
| Knees | $12.3 | $7.8 | $4.5 | 57.1% |
| Hips | $25.3 | $16.6 | $8.8 | 53% |
| Extremities | $26.7 | $17.0 | $9.7 | 57.1% |
| Trauma | $2.7 | $1.7 | $1.0 | 57.1% |
| Other (Promade) | $1.4 | $0.4 | $0.9 | 214.3% |
| Total | $68.4 | $43.6 | $24.9 | 57.1% |
| 1H21 | 1H20 | $ Chg | % Chg | |
|---|---|---|---|---|
| Joint Replacement | $121.0 | $104.5 | $16.5 | 15.8% |
| Knees | $23.1 | $21.1 | $1.9 | 9.1% |
| Hips | $46.8 | $41.2 | $5.6 | 13.7% |
| Extremities | $51.2 | $42.3 | $8.9 | 21.1% |
| Trauma | $5.1 | $4.4 | $0.7 | 16.4% |
| Other (Promade) | $2.0 | $1.1 | $0.9 | 78.6% |
| Total | $128.1 | $110.0 | $18.1 | 16.4% |
Geographic Sales
| 2Q21 | 2Q21 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $11.6 | $7.8 | $3.8 | 48.4% |
| OUS | $56.8 | $35.7 | $21.1 | 59.1% |
| EMEA | $41.1 | $25.3 | $15.8 | 62.6% |
| APAC | $13.0 | $8.3 | $4.7 | 57.1% |
| ROW | $2.7 | $2.2 | $0.6 | 25.7% |
| Total | $68.4 | $43.6 | $24.9 | 57.1% |
| 1H21 | 1H20 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $22.4 | $19.8 | $2.6 | 13% |
| OUS | $105.7 | $90.2 | $15.5 | 17.2% |
| EMEA | $75.7 | $64.5 | $11.2 | 17.3% |
| APAC | $24.9 | $19.6 | $5.4 | 27.4% |
| ROW | $5.1 | $6.2 | ($1.0) | (16.9%) |
| Total | $128.1 | $110.0 | $18.1 | 16.4% |
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
